Selection from HEOR Bibliography
| Search criteria | ||||
| Switzerland |
||||
| The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis | ||||
| Helmut Butzkueven, Jan Hillert, Merja Soilu-Hänninen, Tjalf Ziemssen, Jens Kuhle, Stig Wergeland, Melinda Magyari, Joseph R. Berger, Nicholas Moore, Aida Aydemir, Irene Bezemer & Meritxell Sabidó | ||||
| "a Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia; b The Alfred Hospital, Melbourne, VIC, Australia; c Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; d Turku University Hospital Neurocenter and Division of Clinical Neurosciences, University of Turku, Turku, Finland; e Center of Clinical Neuroscience, Department of Neurology, Dresden University of Technology, Dresden, Germany; f Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland; g Department of Neurology, University Hospital and University of Basel, Basel, Switzerland; h Norwegian MS Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway; i Department of Clinical Medicine, University of Bergen, Bergen, Norway; j Danish Multiple Sclerosis Center and the Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; k Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; l Bordeaux PharmacoEpi (BPE), Universit�e de Bordeaux, Bordeaux, France; m EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA; n Global Epidemiology, IQVIA, Amsterdam, The Netherlands; o Merck Healthcare KGaA, Darmstadt, Germany" | ||||
| , Article | ||||
| , Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey | ||||
| Abstract: https://www.tandfonline.com/doi/full/10.1080/03007995.2023.2256220 | ||||
| Condition | Year | Language | Analysis type | |
| , Comparative Effectiveness & Health Technology Assessment, Drug safety, Neurological disorders | 2023 | English | , clinical setting: Secondary care, Epidemiological study, Population Based Study | |
| Burden of Hospitalizations and Outpatient Visits Associated With Moderate and Severe Acute Graft-Versus-Host Disease in Finland and Sweden: A Real-World Data Analysis | ||||
| Lorenzo Sabatelli, PhD,1 Mikko Keränen, MD, PhD,2 Elisabet Viayna, PhD,3 Montserrat Roset, BSc Stats,3 Nuria Lara, MD, MSc,3 Daniel Thunström, MSc Pharm,1 Minja Pfeiffer, PhD,1 Malin Nicklasson, MSc Pharm,4 Maija Itälä-Remes, MD, PhD5 | ||||
| "1Incyte Biosciences International Sàrl, Morges, Switzerland; 2Helsinki University Hospital, Helsinki, Finland; 3IQVIA Real World Solutions, Barcelona, Spain; 4Department of Hematology and Coagulation, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 5Turku University Hospital, Turku, Finland " | ||||
| Supportive Care in Cancer |
||||
| , Article | ||||
| , Finland, Spain, Sweden, Switzerland | ||||
| Condition | Year | Language | Analysis type | |
| , Health economics, Transplant | 2022 | English | , Clinical setting: hospital, Observational study, Population Based Study | |
| The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets | ||||
| Helmut Butzkueven 1 2, Nicholas Moore 3, Aida Aydemir 4, Jaak Sõnajalg 5, Irene Bezemer 6, Pasi Korhonen 7, Meritxell Sabidó 8, CLARION Study Group | ||||
| 1Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia. 2The Alfred Hospital, Melbourne, Australia. 3Bordeaux PharmacoEpi (BPE), Université de Bordeaux, Bordeaux, France. 4Global Biostatistics, EMD Serono Research & Development Institute, Inc, Billerica, MA, USA (an affiliate of Merck KGaA). 5Global Database Studies, IQVIA, Tartu, Estonia. 6Global Epidemiology and Outcomes Research, IQVIA, Amsterdam, The Netherlands. 7IQVIA (former EPID Research), Espoo, Finland. 8Global Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany. | ||||
| Current Medical Research and Opinion, DOI: 10.1080/03007995.2022.2059977 |
||||
| , Article | ||||
| , Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey | ||||
| Abstract: https://pubmed.ncbi.nlm.nih.gov/35357268/ | ||||
| Condition | Year | Language | Analysis type | |
| , Drug safety, Neurological disorders | 2022 | English | , clinical setting: Secondary care, Epidemiological study, Observational study, Population Based Study, Retrospective database analysis | |
| Healthcare resource utilization and quality of life in patients with sarcoidosis-associated pulmonary hypertension | ||||
| Allan Lawrie1,2|Neil Hamilton3|Steven Wood2,4|Fernando Exposto5|Ruvimbo Muzwidzwa5|Louise Raiteri5|Amélie Beaudet6|Audrey Muller6|Rafael Sauter6|Nadia Pillai6|David G. Kiel | ||||
| 1National Heart and Lung Institute,Imperial College London, London, UK2Insigneo Institute for In‐Silico Medicine,University of Sheffield, Sheffield, UK3Sheffield Pulmonary Vascular DiseaseUnit, Sheffield Teaching Hospitals NHSFoundation Trust, Royal HallamshireHospital, Sheffield, UK4Scientific Computing, Sheffield TeachingHospitals NHS Foundation Trust, RoyalHallamshire Hospital, Sheffield, UK5IQVIA, London, UK6Actelion Pharmaceuticals Ltd.,Allschwil, Switzerland7Department of Infection, Immunity andCardiovascular Disease, University ofSheffield, Sheffield, UK | ||||
| Pulmonary Circulation. 2022;12:e12136.wileyonlinelibrary.com/journal/pul2|1of10https://doi.org/10.1002/pul2.12136 |
||||
| , Article | ||||
| , Switzerland, UK | ||||
| Abstract: https://onlinelibrary.wiley.com/doi/full/10.1002/pul2.12136 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Respiratory disease | 2022 | English | , Observational study, Retrospective cohort analysis | |
| A novel decision model to predict the impact of weight management interventions: The Core Obesity Model. | ||||
| Sandra Lopes 1, Henrik H Meincke 1, Mark Lamotte 2, Anamaria-Vera Olivieri 3, Michael E J Lean 4 | ||||
| 1Novo Nordisk A/S Søborg Denmark. 2IQVIA Zaventem Belgium. 3IQVIA Basel Switzerland. 4Human Nutrition School of Medicine, Dentistry and Nursing Royal Infirmary University of Glasgow Glasgow UK. | ||||
| Obesity Science & Practice 2021. https://doi.org/10.1002/osp4.495 |
||||
| , Article | ||||
| , Belgium, Switzerland | ||||
| Abstract: https://pubmed.ncbi.nlm.nih.gov/34123394 | ||||
| Condition | Year | Language | Analysis type | |
| , Health economics, Obesity | 2021 | English | , Clinical setting: Primary care, Cost effectiveness | |
| Identification of potentially undiagnosed patients with nontuberculous mycobacterial lung disease using machine learning applied to primary care data in the UK | ||||
| Orla M Doyle 1 2, Roald van der Laan 3 2, Marko Obradovic 4 2, Peter McMahon 5, Flora Daniels 6, Ashley Pitcher 7, Michael R Loebinger 8 | ||||
| Predictive Analytics, Real World Analytical Solutions, IQVIA, London, UK. 2These authors contributed equally. 3Insmed Utrecht, Utrecht, The Netherlands. 4Insmed Utrecht, Utrecht, The Netherlands marko.obradovic@insmed.com. 5Real-World Insights, IQVIA, London, UK. 6Real-World Insights, IQVIA, Basel, Switzerland. 7Real-World Insights, IQVIA, Copenhagen, Denmark. 8Royal Brompton and Harefield NHS Foundation Trust and Imperial College London, London, UK. | ||||
| PMID: 32430411 DOI: 10.1183/13993003.00045-2020 |
||||
| , Article | ||||
| , Switzerland, UK | ||||
| Abstract: https://pubmed.ncbi.nlm.nih.gov/32430411/ | ||||
| Condition | Year | Language | Analysis type | |
| , Database Validity and methodology, Pain | 2021 | English | , Population Based Study, Real World Evidence, Retrospective database analysis | |
| Burden of pulmonary arterial hypertension in England: retrospective HES database analysis | ||||
| Fernando Exposto 1, Ruben Hermans 2, Åsa Nordgren 2, Luke Taylor 2, Sanam Sikander Rehman 2, Robert Ogley 2, Evan Davies 3, Amina Yesufu-Udechuku 4, Amélie Beaudet | ||||
| IQVIA, 210 Pentonville Road, London, N1 9JY, UK. 2IQVIA, London, UK. 3Actelion Pharmaceuticals Ltd, Allschwil, Basel-Landschaft, Switzerland. 4Actelion Pharmaceuticals UK Ltd, High Wycombe, UK. | ||||
| Ther Adv Respir Dis. 2021 Jan-Dec; 15: 1753466621995040. Published online 2021 Feb 23. doi: 10.1177/1753466621995040 |
||||
| , Article | ||||
| , Switzerland, UK | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905485/ | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Respiratory disease | 2021 | English | , Burden of illness | |
| Bridging the Gap Between RCTs and RWE Through Endpoint Selection | ||||
| Robert J LoCasale 1, Chris L Pashos 2, Ben Gutierrez 3, Nancy A Dreyer 4, Toby Collins 5, Alan Calleja 5, Michael J Seewald 6, Jonathan M Plumb 7, Johan Liwing 8, Maurille Feudjo Tepie 9, Sajan Khosla 10 | ||||
| 1Real World Evidence, Sanofi, Bridgewater, NJ, USA. 2AbbVie, Chicago, IL, USA. 3GSK, Philadelphia, PA, USA. 4IQVIA, Real-World Solutions, Cambridge, MA, USA. 5IQVIA, Real-World Solutions, London, UK. 6Novartis Pharma AG/Pharma Medical Affairs, Basel, Switzerland. 7Ferring Pharmaceuticals SA, St Prex, Switzerland. 8CellProtect Nordic Pharmaceuticals, Stockholm, Sweden. 9Center for Observational Research, Amgen, Cambridge, UK. 10Real-World Evidence Center of Excellence, AstraZeneca, Cambridge, UK. sajan.khosla@astrazeneca.com. | ||||
| Published online 2020 Jul 6. doi: 10.1007/s43441-020-00193-5 |
||||
| , Article | ||||
| , Sweden, Switzerland, UK, USA | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785541/ | ||||
| Condition | Year | Language | Analysis type | |
| , Health status & patient reported outcomes | 2020 | English | , Real World Data, Real World Evidence | |
| External Validation of the Core Obesity Model to Assess the Cost Effectiveness of Weight Management Interventions | ||||
| Sandra Lopes 1, Pierre Johansen 2, Mark Lamotte 3, Phil McEwan 4, Anamaria-Vera Olivieri 5, Volker Foos 4 | ||||
| 1Novo Nordisk A/S, Søborg, Denmark. snlb@novonordisk.com. 2Novo Nordisk A/S, Søborg, Denmark. 3IQVIA, Zaventem, Belgium. 4Health Economics and Outcomes Research Ltd, Cardiff, UK. 5IQVIA, Basel, Switzerland. | ||||
| Pharmacoeconomics 2020 https://doi.org/10.1007/s40273-020-00941-3 + Pharmacoeconomics. 2021 Jan;39(1):137-138. doi: 10.1007/s40273-020-00982-8. Epub 2020 Nov 30 |
||||
| , Article | ||||
| , Belgium, Denmark, Switzerland, UK | ||||
| Abstract: https://pubmed.ncbi.nlm.nih.gov/32656686/ | ||||
| Condition | Year | Language | Analysis type | |
| , Health economics, Obesity | 2020 | English | , Clinical setting: Primary care, Cost effectiveness | |
| A Survey Among Health Care Professionals to Assess Their Knowledge and Understanding on Darzalex® (Daratumumab) Educational Materials Regarding the Risk of Interference for Blood Typing in 12 European Countries | ||||
| Mathieu Rosé, Intissar Bourahla, Alessandro Ghiddi, Assem Al-Akabawi, Edmond Chan, Massoud Toussi | ||||
| IQVIA, Courbevoie, France; Janssen EMEA, Medical Affairs, Italy; Janssen EMEA, Medical Affairs, UK | ||||
| Presented at ISPE’s 35th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE 2019), August 24–28, 2019 at the Pennsylvania Convention Center, Philadelphia, PA, USA. |
||||
| , Poster | ||||
| , Austria, Czech, Denmark, Finland, France, Germany, Hungary, Norway, Slovakia, Spain, Sweden, Switzerland | ||||
| Abstract: https://www.coodoc.com/pages/p1822-Daratumumab-ICPE-2019 | ||||
| Condition | Year | Language | Analysis type | |
| , Hematology, Oncology | 2019 | English | , Public Health, Survey research | |
| No increased risk of spontaneous abortion and ectopic pregnancy after exposure to interferon-beta prior to or during pregnancy: Results from register-based Nordic study among women with MS | ||||
| R. Juuti1, K. M. Hakkarainen 1, S. Burkill 2, Y. Geissbuehler 3, M. Sabidó 4, C. Popescu 5, A. Adamo 6, J. Hillert 2, S. Cnattingius 2, M. Artama 7, A. Verkkoniemi-Ahola 8, K.-M. Myhr 9, J. Mehtälä 1, S. Bahmanyar 2, S. Montgomery 2,10, P. Korhonen 1 and the European Interferon Beta Pregnancy Study Group | ||||
| 1StatFinn-EPID Research, Espoo, Finland | ||||
| EAN, Oslo, Norway, June 29-2 July, 2019 |
||||
| , Oral presentation | ||||
| , Finland, Germany, Norway, Sweden, Switzerland, UK | ||||
| Abstract: https://www.ean.org/fileadmin/_files/AbstractBook/EAN_Journal_2019_Book.pdf | ||||
| Condition | Year | Language | Analysis type | |
| , Neurological disorders | 2019 | English | , Epidemiological study, Population Based Study, Retrospective database analysis | |
| Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Europe | ||||
| Kotseva K1, Gerlier L2, Sidelnikov E3, Kutikova L3, Lamotte M2, Amarenco P4, Annemans L5 | ||||
| 1 Department of Cardiovascular Medicine, National Heart and Lung Institute, Imperial College London, UK 2 IQVIA, Zaventem, Belgium 3 Amgen (Europe) GmbH, Rotkreuz, Switzerland 4 Department of Neurology and Stroke Centre, Bichat Hospital, Paris, France 5 University of Ghent, Belgium | ||||
| Eur J Prev Cardiol. 2019 Jul;26(11):1150-1157. |
||||
| , Article | ||||
| , Belgium, France, Poland, Portugal, Spain, Switzerland, UK | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/30955367 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Health economics | 2019 | English | , Burden of illness, Clinical setting: Primary care, direct to patient research, Observational study | |
| Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Europe. | ||||
| Kotseva K1, Gerlier L2, Sidelnikov E3, Kutikova L3, Lamotte M2, Annemans L4, Amarenco P5 | ||||
| 1 Imperial College London, London, United Kingdom 2 IQVIA, Zaventem, Belgium 3 Amgen Europe GmbH, Zug, Switzerland 4 Ghent University, Ghent, Belgium 5 Hospital Bichat-Claude Bernard, Paris, France | ||||
| European Society of Cardiology (ESC) Congress, 2018, Munich, Germany |
||||
| , Poster | ||||
| , Belgium, France, Poland, Portugal, Spain, Switzerland, UK | ||||
| Abstract: https://esc365.escardio.org/Congress/ESC-Congress-2018/Poster-Session-3-Health-economics/176943-patient-and-caregiver-productivity-loss-and-indirect-costs-associated-with-cardiovascular-events-in-europe | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Health economics | 2018 | English | , Burden of illness, Cost of illness | |
| COMMONALITIES AND DIFFERENCES IN DATA COLLECTION ACROSS EUROPEAN SPONDYLOARTHRITIS REGISTRIES | ||||
| M. L. Hetland* 1, M. Østergaard1, J. Askling2, C. Gabay3, D. Nordstrom4, O. FitzGerald5, M. Hernández Miguel6, M. Santos7 , Z. Rotar8, H. Mann9, F. Iannone10, M. J. Nissen3, E. Hauge1, J. Gomez-Reino11, F. Díaz-González12, M. Tomsic8, K. Pavelka9, F. O'Shea5, C. Sullivan5, M. van de Sande13, I. E. van der Horst-Bruinsma13, G. J. Macfarlane14, G. T. Jones14, B. Gudbjørnsson15, T. K. Kvien16 on behalf of EuroSpA Study Group | ||||
| 1DANBIO, Glostrup, Denmark, 2ARTIS, Stockholm, Sweden, 3SCQM, Geneva, Switzerland, 4ROB-FIN, Helsinki, Finland, 5ASRI, Dublin, Ireland, 6BIOBADASER, Barcelona, Spain, 7reuma.pt, Almada, Portugal, 8biorx.si, Ljubljana, Slovenia, 9ATTRA, Prague, Czech Republic, 10GISEA, Bari, Italy, 11BIOBADASER, Santiago, 12BIOBADASER, Santa Cruz de Tenerife, Spain, 13ARC, Amsterdam, Netherlands, 14BSRBR-AS, Aberdeen, United Kingdom, 15ICEBIO, Reykjavik, Iceland, 16NORDMARD, Oslo, Norway | ||||
| EULAR, Madrid, 2017 |
||||
| , Abstract | ||||
| , Czech, Denmark, Finland, Ireland, Italy, Norway, Slovenia, Spain, Sweden, Switzerland | ||||
| Abstract: http://ard.bmj.com/content/76/Suppl_2/656.3 | ||||
| Condition | Year | Language | Analysis type | |
| , Rheumatology | 2017 | English | , Epidemiological study | |
| Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature. | ||||
| Svedman FC1, Pillas D2, Taylor A2, Kaur M2, Linder R3, Hansson J1. | ||||
| 1Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden. 2Centre for Observational Research, Amgen Ltd, Uxbridge, UK. 3IMS Health Sweden, Stockholm, Sweden. | ||||
| Clinical Epidemiology |
||||
| , Article | ||||
| , Australia, Austria, Belgium, Bulgaria, Croatia, Czech, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Serbia and Montenegro, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, UK | ||||
| Abstract: http://www-ncbi-nlm-nih-gov.proxy.kib.ki.se/pmc/articles/PMC4887072/ | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2016 | English | , Literature Review | |
| Rationale and design of a multi-center survey to evaluate productivity losses and indirect costs after cardiovascular events in Europe. | ||||
| Gerlier L1, Sidelnikov E2, Kutikova L2, Lamotte M1, Annemans L3 | ||||
| 1 QuintilesIMS, Zaventem, Belgium 2 Amgen (Europe) GmbH, Zug, Switzerland 3 University of Ghent, Ghent, Belgium | ||||
| 19th ISPOR Annual European Congress, 2016, October 29- November 2, Vienna, Austria |
||||
| , Abstract | ||||
| , Belgium, Czech, France, Germany, Hungary, Italy, Poland, Portugal, Romania, Spain, Switzerland, UK | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2016 | English | ||
| Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study. | ||||
| Peyrin-Biroulet L1, Van Assche G2, Sturm A3, Gisbert JP4, Gaya DR5, Bokemeyer B6, Mantzaris GJ7, Armuzzi A8, Sebastian S9, Lara N10, Lynam M10, Rojas-Farreras S10, Fan T11, Ding Q11, Black CM11, Kachroo S11. | ||||
| 1Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, Lorraine University, Vandoeuvre-lès-Nancy, France. Electronic address: peyrinbiroulet@gmail.com. 2Division of Gastroenterology, University Hospitals Leuven, Leuven Belgium. 3Department of Gastroenterology, DRK Kliniken Berlin I Westend, Berlin, Germany. 4Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. 5Gastroenterology Unit, Glasgow Royal Infirmary, Glasgow, United Kingdom. 6Gastroenterology Practice, Minden, Germany. 7Department of Gastroenterology, Evangelismos Hospital, Athens, Greece. 8IBD Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy. 9Gastroenterology and IBD Unit, Hull and East Yorkshire Hospitals NHS Trust, Hull, United Kingdom. 10IMS Health, Real World Evidence Solutions, Spain. 11Merck & Co., Inc., Kenilworth, NJ, United States | ||||
| Dig Liver Dis. 2016 Jun;48(6):601-7. |
||||
| , Article | ||||
| , Belgium, France, Germany, Greece, Italy, Netherlands, Spain, Sweden, Switzerland, Turkey, UK | ||||
| Condition | Year | Language | Analysis type | |
| , Gastrointestinal disorders | 2016 | English | , Burden of illness, Patient questionnaire, Survey research | |
| Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study | ||||
| Van Assche G1, Peyrin-Biroulet L2, Sturm A3, Gisbert JP4, Gaya DR5, Bokemeyer B6, Mantzaris GJ7, Armuzzi A8, Sebastian S9, Lara N10, Lynam M10, Rojas-Farreras S10, Fan T11, Ding Q11, Black CM11, Kachroo S11. | ||||
| 1Division of Gastroenterology, University Hospitals Leuven, Leuven, Belgium. Electronic address: gert.vanassche@uzleuven.be. 2Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, Lorraine University, Vandoeuvre-lès-Nancy, France. 3Department of Gastroenterology, DRK Kliniken Berlin I Westend, Berlin, Germany. 4Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica and Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. 5Gastroenterology Unit, Glasgow Royal Infirmary, Glasgow, UK. 6Gastroenterology Practice, Minden, Germany. 7Department of Gastroenterology, Evangelismos Hospital, Athens, Greece. 8IBD Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy. 9Gastroenterology and IBD Unit, Hull and East Yorkshire Hospitals NHS Trust, Hull, UK. 10IMS Health, Real World Evidence Solutions, Barcelona, Spain. 11Merck & Co., Inc., Rahway, NJ, United States. | ||||
| Dig Liver Dis. 2016 Jun;48(6):592-600 |
||||
| , Article | ||||
| , Belgium, France, Germany, Greece, Italy, Netherlands, Spain, Sweden, Switzerland, Turkey, UK | ||||
| Condition | Year | Language | Analysis type | |
| , Gastrointestinal disorders | 2016 | English | , Burden of illness, Patient questionnaire | |
| ESTIMATION OF DIRECT MEDICAL COSTS ASSOCIATED WITH TREATMENT OF METASTATIC MELANOMA IN SWITZERLAND | ||||
| Christoffersen P1, Khan N1, Lucas J1, Christodoulopoulou A2, Del Ponte A2, Gutzwiller F2 | ||||
| 1IMS Health, Basel, Switzerland, 2Amgen Switzerland AG, Zug, Switzerland | ||||
| ISPOR 18th Annual European Congress Milan, Italy November, 2015 |
||||
| , Poster | ||||
| , Switzerland | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2015 | English | ||
| Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland | ||||
| Samyshkin Y1, Schlunegger M2, Haefliger S3, Ledderhose S3, Radford M1 | ||||
| 1 IMS Health, HEOR, London, UK 2 Marketing Specialty Care 3 Takeda Pharma AG, Pfäffikon, Switzerland | ||||
| International Journal of COPD 8:79-87 |
||||
| , Article | ||||
| , Switzerland | ||||
| Condition | Year | Language | Analysis type | |
| , Respiratory disease | 2013 | English | , Cost effectiveness | |
| Treatment cost of acute coronary syndrome with ticagrelor compared to clopidogrel in Switzerland. | ||||
| Gasche D1, Ulle T2, Meier B3, Greiner RA1 | ||||
| 1 IMS Health, Munich, Germany 2 AstraZeneca AG, Zug, Switzerland 3 Department of Cardiology, Bern University Hospital, Bern, Switzerland | ||||
| Gemeinsamen Jahrestagung der Schweizerischen Gesellschaften für Kardiologie und der Schweizerischen Gesellschaft für Herz- und Thorakale Gefässchirurgie - in press, 2013. |
||||
| , Poster | ||||
| , Switzerland | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2013 | English | , Cost analysis | |
| Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden. | ||||
| Valentine WJ1, Aagren M2, Haglund M3-4, Ericsson A3, Gschwend MH5 | ||||
| 1Ossian Health Economics and Communication, Basel, Switzerland, 2Novo Nordisk Inc., Princeton, NJ, USA, 3Novo Nordisk Scandinavia AB, Malmo, Sweden, 4NeuroSearch A/S, Ballerup, Denmark and 5IMS Health, Basel, Switzerland | ||||
| Scandinavian journal of public health |
||||
| , Manuscript in preparation | ||||
| , Nordic, Switzerland | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/20688795 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Cost effectiveness | |
| Cost-effectiveness of Roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland | ||||
| Samyshkin Y1, Radford M1, Schlunegger M2, Gooss A2 | ||||
| 1IMS Health, London, UK, 2Nycomed Pharma AG, Dübendorf, Switzerland | ||||
| ISPOR 14th Annual European Conference, 5-8 November 2011, Madrid, Spain |
||||
| , Poster | ||||
| , Switzerland | ||||
| Abstract: http://www.ispor.org/congresses/Spain1111/Posters3.aspx | ||||
| Condition | Year | Language | Analysis type | |
| , Respiratory disease | 2011 | English | , Cost effectiveness | |
| Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. | ||||
| Jose´ R. Banegas 1,2*, Esther Lo´pez-Garcı´a 1,2, Jean Dallongeville3, Eliseo Guallar 4,5,6,7, Julian P. Halcox8, Claudio Borghi 9, Elvira L. Masso´-Gonza´lez 10, Francisco J. Jime´nez 11, Joep Perk12, Philippe Gabriel Steg13, Guy De Backer 14,and Fernando Rodrı´guez-Artalejo1,2 | ||||
| 1 Department of Preventive Medicine and Public Health, School of Medicine, Universidad Auto´noma de Madrid/IdiPAZ, Avda Arzobispo Morcillo, 2, 28029 Madrid, Spain; 2 CIBER of Epidemiology and Public Health, Madrid, Spain; 3 Inserm U 744, Institut Pasteur de Lille, 59019 Lille Cedex, France; 4 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 5 Department of Medicine, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 6 Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 7 Department of Cardiovascular Epidemiology and Population Genetics, National Center for Cardiovascular Research (CNIC), Madrid 28029, Spain; 8 Wales Heart Research Institute, Cardiff University, Heath Park, Cardiff CF14 4XN, UK; 9 Department of Internal Medicine, Aging and Clinical Nephrology, University of Bologna, Bologna, Italy; 10Medical Department, AstraZeneca Farmace´utica Spain, S.A., 28003 Madrid, Spain; 11Medical Department, AstraZeneca Europe, 1935 Zaventem, Belgium; 12School of Health and Caring Sciences, Linnaeus University, 391 82 Kalmar, Sweden; 13INSERM U 698, Assistance Publique–Hoˆpitaux de Paris and Universite´ Paris-Diderot, Paris, France; and 14Department of Public Health, University of Gent, 9000 Gent, Belgium | ||||
| Eur Heart J. 2011 Sep;32(17):2143-52 |
||||
| , Article | ||||
| , Austria, Belgium, France, Germany, Greece, Norway, Spain, Sweden, Switzerland, Turkey, UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21471134 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2011 | English | , Observational study, Prospective study | |
| Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study. | ||||
| Guallar E, Banegas JR, Blasco-Colmenares E, Jiménez FJ, Dallongeville J, Halcox JP, Borghi C, Massó-González EL, Tafalla M, Perk J, De Backer G, Steg PG, Rodríguez-Artalejo F. | ||||
| BMC Public Health. 2011 Sep 18;11:704. doi: 10.1186/1471-2458-11-704. |
||||
| , Article | ||||
| , Austria, Belgium, France, Germany, Greece, Norway, Russian Federation, Spain, Sweden, Switzerland, Turkey, UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21923932 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2011 | English | , Observational study, Prospective study | |
| Health care-associated rotavirus illness in pediatric inpatients in Germany, Austria, and Switzerland. | ||||
| Foppa I, Karmaus W, Ehlken B, Fruhwirth M, Heiniger U, Plenge-Bonig A, Forster J. | ||||
| Infect Control Hosp Epidemiol. 2006; 27(6): 633-5. |
||||
| , Article | ||||
| , Austria, Germany, Switzerland | ||||
| Condition | Year | Language | Analysis type | |
| , Infectious disease | 2006 | English | , Epidemiological study | |